What are research peptides?

A working definition

A peptide is a chain of amino acids joined by amide linkages, formed when the carboxyl group of one residue condenses with the amino group of the next and a molecule of water is released. That linkage — the peptide bond — has partial double-bond character, which means it is planar and rotationally restricted. Almost everything that makes peptides behave the way they do in the laboratory follows from this single structural fact.

Because rotation is restricted at the bond itself but free at the flanking alpha carbons, a peptide chain occupies a constrained but still enormous conformational space. Short sequences sample many conformations in solution; longer ones begin to adopt stable secondary structures such as helices and sheets.

A research peptide is simply a peptide manufactured, tested and released for laboratory investigation rather than for clinical supply. The molecule is the same class of chemistry; the difference lies entirely in the specification it is made against and the use it may lawfully be sold for.

Where peptides end and proteins begin

There is no formal boundary, only convention. Chains up to roughly 50 residues are generally called peptides; beyond that, the term protein is preferred because tertiary folding and domain organisation become the dominant description. Most research compounds in circulation sit well below that line — between three and forty residues.

The practical consequence is production route. Sequences under about 50 residues are usually made by solid-phase synthesis, where the chain is assembled residue by residue on a resin. Longer molecules are typically produced recombinantly in a host organism, which is why materials such as IGF-1 LR3 behave more like proteins in handling terms than like short synthetic peptides.

How research peptides are synthesised

The dominant method is solid-phase peptide synthesis (SPPS), introduced by Merrifield in 1963 and still the backbone of the industry. The C-terminal residue is anchored to an insoluble resin bead, its protecting group is removed, and the next activated amino acid is coupled. Deprotection and coupling alternate until the sequence is complete, after which the chain is cleaved from the resin and the side-chain protecting groups are stripped.

Each coupling step is efficient but not perfect. A 99 percent yield per cycle across a thirty-residue sequence still leaves roughly a quarter of the crude material as truncated or deletion sequences — chains missing one or more residues. Those impurities are chemically similar to the target, which is why crude synthetic peptide is never usable as-is and why the purification step, not the synthesis, determines the grade of the final material.

Purification is normally preparative reversed-phase HPLC, separating the target from close-eluting deletion sequences by hydrophobicity. The purified fraction is then lyophilized — freeze-dried under vacuum — into the white cake found in a research vial. Recombinant production replaces this route entirely for longer sequences, using expression in bacterial or yeast hosts followed by chromatographic capture and polishing.

Purity standards and what they actually measure

Purity on a certificate of analysis is almost always chromatographic purity: the area of the target peak as a percentage of total integrated peak area by RP-HPLC at a stated wavelength. A figure of 99 percent means the target accounts for 99 percent of UV-absorbing material detected — it does not mean the vial is 99 percent peptide by mass.

Net peptide content is the separate figure that answers that question. Lyophilized peptide carries residual water and counter-ions, typically trifluoroacetate from purification, so a vial of 99 percent pure material may be only 75 to 90 percent peptide by weight. Studies that depend on accurate molar concentration must use net peptide content, not the label strength, when calculating.

Identity is a third, independent check. Mass spectrometry confirms the observed molecular weight matches the theoretical mass for the stated sequence and its terminal modifications. Purity without identity confirms only that one compound dominates the sample; it does not confirm which compound. A complete certificate reports all three, tied to a specific lot number, from a named independent laboratory.

What 'research grade' actually designates

Research grade material is manufactured and released against research specifications rather than pharmacopoeial ones. There is no representation of sterility, no endotoxin or pyrogen limit, no compliance with pharmaceutical GMP, and no regulatory evaluation of safety or efficacy. It is a reagent, supplied for in vitro and appropriately approved preclinical work.

That is the whole of the distinction between a research peptide and a pharmaceutical one. A compound can be legally purchased and held as a laboratory reagent while remaining an unapproved new drug the moment it is offered or used for human or veterinary administration. The designation attaches to purpose and representation, not to the molecule.

In practice this shapes what a credible supplier will and will not do. Lot-specific third party analytics, plain research use only terms, and refusal to discuss administration are the norm. Dosing charts, outcome claims, testimonials, or copy written about what a compound will do for the reader all indicate a vendor operating outside research-supply conventions — and their analytical claims warrant the same scepticism.

Why sequence notation matters

Sequences are written N-terminus to C-terminus, left to right. Modifications are indicated inline: Ac- for N-terminal acetylation, -NH2 for a C-terminal amide, D- for a D-configuration residue, and bracketed notation for cyclisation points. Two materials with an identical residue list but different terminal chemistry are different compounds with different masses, different stability and different receptor behaviour.

This is why a certificate of analysis reports both the sequence and the observed mass. Mass spectrometry confirms that the terminal modifications and any bridges are present as specified, which a purity chromatogram alone cannot establish.

Handling: the short version

Lyophilized peptide is stable for extended periods at -20 °C, protected from light and moisture. The cake is hygroscopic, so vials should be brought to room temperature before opening to avoid condensation drawing water into the powder. Once reconstituted, stability is measured in weeks under refrigeration rather than months, and freeze-thaw cycling degrades most sequences faster than storage time does.

Solvent choice depends on the sequence. Bacteriostatic water is standard for routine work; strongly hydrophobic or aggregation-prone sequences may need a small volume of dilute acetic acid or another co-solvent first. Copper-containing peptides such as GHK-Cu are incompatible with reducing agents and free-cysteine sequences and should be reconstituted separately.

How a research peptide is actually made

Almost every short sequence sold as a research peptide is built by solid-phase synthesis, a method that assembles the chain one residue at a time while it stays anchored to an insoluble resin bead. Each cycle removes a protecting group from the growing chain's free amine, couples the next protected amino acid using an activating reagent, and washes the excess away. Because the product never leaves the bead until the end, purification between steps is a filtration rather than a chromatography run, which is what makes the approach practical at all.

The consequence that matters analytically is arithmetic. If each coupling proceeds at 99% efficiency, a ten-residue peptide finishes at roughly 90% full-length material, while a forty-residue peptide finishes near 67%. The missing fraction is not waste but a family of closely related impurities — chains one residue short, chains carrying a residual protecting group, chains oxidised at methionine or cysteine. Longer sequences are therefore harder to purify, which is why a 39-residue incretin analog and a five-residue secretagogue are not comparable manufacturing problems even when both are quoted at the same purity.

After cleavage from the resin the crude material is purified by preparative reversed-phase HPLC, pooled from the fractions that meet specification, and lyophilized into the amorphous cake supplied in the vial. Sequences longer than roughly fifty residues are usually produced recombinantly instead, because the stepwise yield of chemical synthesis stops being economic.

Reading a specification the way a laboratory does

Three numbers describe a released lot and they answer three different questions. Chromatographic purity answers what fraction of the UV-absorbing material in the run is the target peak. Net peptide content answers how much of the powder in the vial is actually peptide rather than counter-ion and residual water. Mass-spectrometric identity answers whether the target peak is the intended sequence at all. A certificate that reports only the first has answered one third of the question.

The gap between the first two figures surprises people the first time they see it. A lot reported at 99% chromatographic purity is frequently only 75% to 90% peptide by mass, because trifluoroacetate or acetate counter-ions from purification and residual moisture in the cake both contribute weight without contributing peptide. Any calculation that converts a fill weight into a molar concentration has to start from net peptide content, and any laboratory reporting an EC50 from nominal fill weight has built a systematic error into the number.

Identity is the check that catches the failure modes purity cannot see. A deletion analog missing one residue can elute close enough to the parent to sit inside the main peak on a short gradient, but it differs in mass by the residue's exact contribution and is unambiguous on a mass spectrum. This is the reason independent HPLC and mass spectrometry are run together on every lot in our catalogue rather than one standing in for the other.